PNC Financial Services Group’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
PNC Financial Services Group's TRDA Position: Q3 2026 in Review
PNC Financial Services Group increased its Entrada Therapeutics (TRDA) stake by 14% in Q3 2026, buying an estimated $1.12K and bringing the position to 1,296 shares worth $8.23K. The position accounts for ﹤0.01% of the portfolio, ranked #4268.
PNC Financial Services Group first reported a position in TRDA in Q1 2023 and has held it in 7 quarters since. The position peaked at $14.4K in Q1 2026. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- PNC Financial Services Group held 1,296 shares of Entrada Therapeutics worth $8.23K as of Q3 2026.
- PNC Financial Services Group bought 161 Entrada Therapeutics shares in Q3 2026, an estimated $1.12K.
- Entrada Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4268 holding.
- PNC Financial Services Group first reported a position in Entrada Therapeutics in Q1 2023 and has held it in 7 quarters since.
- PNC Financial Services Group's Entrada Therapeutics position peaked at $14.4K in Q1 2026.
- 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.